In our current analyses, we identified a subset of MSS CRC that is hypermutated due to mutations in the POLE gene; however, we did not find any striking differences in the immune profiles of tumor cells and TILs between POLE-mutant and POLE-wild-type CRCs, unlike cases with an MMR deficiency. This evidence concerns the gene POLE and colorectal carcinoma.